Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Correction to "Cathepsin-Targeting SARS-CoV-2 Inhibitors: Design, Synthesis, and Biological Activity".
Flury P, Breidenbach J, Krüger N, Voget R, Schäkel L, Si Y, Krasniqi V, Calistri S, Olfert M, Sylvester K, Rocha C, Ditzinger R, Rasch A, Pöhlmann S, Kronenberger T, Poso A, Rox K, Laufer SA, Müller CE, Gütschow M, Pillaiyar T. Flury P, et al. Among authors: rox k. ACS Pharmacol Transl Sci. 2024 Mar 6;7(4):1195-1196. doi: 10.1021/acsptsci.4c00095. eCollection 2024 Apr 12. ACS Pharmacol Transl Sci. 2024. PMID: 38633592 Free article.
Cathepsin-Targeting SARS-CoV-2 Inhibitors: Design, Synthesis, and Biological Activity.
Flury P, Breidenbach J, Krüger N, Voget R, Schäkel L, Si Y, Krasniqi V, Calistri S, Olfert M, Sylvester K, Rocha C, Ditzinger R, Rasch A, Pöhlmann S, Kronenberger T, Poso A, Rox K, Laufer SA, Müller CE, Gütschow M, Pillaiyar T. Flury P, et al. Among authors: rox k. ACS Pharmacol Transl Sci. 2024 Jan 19;7(2):493-514. doi: 10.1021/acsptsci.3c00313. eCollection 2024 Feb 9. ACS Pharmacol Transl Sci. 2024. PMID: 38357286
Drug repurposing screen identifies lonafarnib as respiratory syncytial virus fusion protein inhibitor.
Sake SM, Zhang X, Rajak MK, Urbanek-Quaing M, Carpentier A, Gunesch AP, Grethe C, Matthaei A, Rückert J, Galloux M, Larcher T, Le Goffic R, Hontonnou F, Chatterjee AK, Johnson K, Morwood K, Rox K, Elgaher WAM, Huang J, Wetzke M, Hansen G, Fischer N, Eléouët JF, Rameix-Welti MA, Hirsch AKH, Herold E, Empting M, Lauber C, Schulz TF, Krey T, Haid S, Pietschmann T. Sake SM, et al. Among authors: rox k. Nat Commun. 2024 Feb 8;15(1):1173. doi: 10.1038/s41467-024-45241-y. Nat Commun. 2024. PMID: 38332002 Free PMC article. Review.
Inhibitors of the Elastase LasB for the Treatment of Pseudomonas aeruginosa Lung Infections.
Konstantinović J, Kany AM, Alhayek A, Abdelsamie AS, Sikandar A, Voos K, Yao Y, Andreas A, Shafiei R, Loretz B, Schönauer E, Bals R, Brandstetter H, Hartmann RW, Ducho C, Lehr CM, Beisswenger C, Müller R, Rox K, Haupenthal J, Hirsch AKH. Konstantinović J, et al. Among authors: rox k. ACS Cent Sci. 2023 Oct 27;9(12):2205-2215. doi: 10.1021/acscentsci.3c01102. eCollection 2023 Dec 27. ACS Cent Sci. 2023. PMID: 38161367 Free PMC article.
Pharmacokinetic and pharmacodynamic evaluation of the atypical tetracyclines chelocardin and amidochelocardin in murine infection models.
Rox K, Jansen R, Lukežič T, Greweling-Pils M, Herrmann J, Miethke M, Hüttel S, Hennessen F, Abou Fayad A, Holzhausen C, Lundberg CV, Teague J, Sudarman E, Bülter L, Hesterkamp T, Stadler M, Brönstrup M, Müller R. Rox K, et al. Microbiol Spectr. 2024 Jan 11;12(1):e0128923. doi: 10.1128/spectrum.01289-23. Epub 2023 Dec 4. Microbiol Spectr. 2024. PMID: 38047701 Free PMC article.
Discovery of highly neutralizing human antibodies targeting Pseudomonas aeruginosa.
Simonis A, Kreer C, Albus A, Rox K, Yuan B, Holzmann D, Wilms JA, Zuber S, Kottege L, Winter S, Meyer M, Schmitt K, Gruell H, Theobald SJ, Hellmann AM, Meyer C, Ercanoglu MS, Cramer N, Munder A, Hallek M, Fätkenheuer G, Koch M, Seifert H, Rietschel E, Marlovits TC, van Koningsbruggen-Rietschel S, Klein F, Rybniker J. Simonis A, et al. Among authors: rox k. Cell. 2023 Nov 9;186(23):5098-5113.e19. doi: 10.1016/j.cell.2023.10.002. Epub 2023 Nov 1. Cell. 2023. PMID: 37918395
Sorangicin A Is Active against Chlamydia in Cell Culture, Explanted Fallopian Tubes, and Topical In Vivo Treatment.
Graspeuntner S, Koethke K, Scholz C, Semmler L, Lupatsii M, Kirchhoff L, Herrmann J, Rox K, Wittstein K, Käding N, Hanker LC, Stadler M, Brönstrup M, Müller R, Shima K, Rupp J. Graspeuntner S, et al. Among authors: rox k. Antibiotics (Basel). 2023 Apr 22;12(5):795. doi: 10.3390/antibiotics12050795. Antibiotics (Basel). 2023. PMID: 37237698 Free PMC article.
36 results